Targeting these cytokines has been a major therapeutic strategy for managing IBD, leading to the development of biologic therapies that specifically inhibit IL-6 or TNF-α signaling pathways (Alhendi and Naser 2023; Shahini and Shahini 2023). This evidence concerns the gene IL6 and inflammatory bowel disease.